The Brighterside of News on MSN
New drug combo cuts risk of death for men with prostate cancer by 40%
Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...
A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...
A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...
Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) ...
On-treatment PSA and disease burden should be considered together for prognostication. Achieving PSA ≤0.2 ng/mL within 6–12 weeks strongly predicts favorable long-term survival. Metastatic volume and ...
BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...
Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.
Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...
The Gleason score reliably predicts lethal prostate cancer for up to 25 years after diagnosis. High-grade prostate cancers progress rapidly in the short term, while lower grade tumors can still lead ...
Grape seed extract—a dietary supplement made from the seeds of wine grapes—has been investigated to see if it can help reduce ...
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...
A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback